Metraipolis › archive › dc_95db1f5fa506

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus… — Europe PMC PMID:41694351

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41694351
DOI
10.3389/fimmu.2026.1729883
License (as archived)
solo-consultazione
Archived
2026-11-06T11:10:20.375Z
SHA-256 of the archived text
c804c809b78a71de504ae707c29ac94cd1e705f70cf7a147d54d122187282510
Stable URL of this page
https://metraipolis.com/documento/dc_95db1f5fa506

How to cite

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus… — Europe PMC PMID:41694351 — Europe PMC (en), https://europepmc.org/article/MED/41694351 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_95db1f5fa506 (Metraipolis archive dc_95db1f5fa506, sha256 c804c809b78a71de504ae707c29ac94cd1e705f70cf7a147d54d122187282510)
BibTeX
@misc{dc95db1f5fa506,
  title = {A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus… — Europe PMC PMID:41694351},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41694351},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_95db1f5fa506; sha256 c804c809b78a71de504ae707c29ac94cd1e705f70cf7a147d54d122187282510},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41694351. Agents can read the archived copy with the MCP tool read_document.